Your search for oral corticosteroids returned 161 results

Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis.

Oral corticosteroid dosage reduction sustained in open-label extension study of dupilumab

Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.

Compared to the control group, patients who took four or more oral corticosteroid prescriptions had 1.29 times the odds of experiencing a new adverse effect within the year.

Patients with asthma are at higher risk of pulmonary embolism, particularly if the asthma is severe or they take oral corticosteroids.

Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.

Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine

Highest rates of adverse events seen within first month after initiating short course of oral steroids.

Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.

Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…